Loading organizations...
§ Private Profile · Abingdon, Oxfordshire, United Kingdom
Biotech developing T cell receptor immunotherapies, including KIMMTRAK, for solid tumors, infectious, and autoimmune diseases
Immunocore is a commercial-stage biotechnology company based in Abingdon, United Kingdom, focused on developing T cell receptor-based immunotherapies for cancer, infectious diseases, and autoimmune conditions. The company utilizes its proprietary ImmTAC molecules to redirect T cells, notably developing KIMMTRAK, the first bispecific T cell receptor therapy approved for solid tumors like uveal melanoma. With approximately 400 employees, Immunocore raised significant capital, including a $320 million private financing round in 2015 and $40 million from the Bill & Melinda Gates Foundation in 2017. Led by CEO Bahija Jallal and with Professor Sir John Bell as Board Chairman, the company is listed on NASDAQ under the ticker IMCR. Immunocore was founded in 2008 by Bent Jakobsen, George Edward Silvanus Robinson, Nicholas John Cross, James Noble, and George Kelly Martin.
Immunocore has raised $664.8M across 4 funding rounds.
Immunocore has raised $664.8M in total across 4 funding rounds.
Immunocore has raised $664.8M across 4 funding rounds. Most recently, it raised $175.0M Debt / Series C in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 13, 2021 | $175M Debt Financing | BlackRock | Oxford Finance | Announced |
| Mar 18, 2020 | $130M Series B | ROB Perez | Bill & Melinda Gates Foundation, CCB International, ELI Lilly And Company, JDRF T1D Fund, Rock Springs Capital, RTW Investments, Terra Magnum Capital Partners, WuXi AppTec | Announced |
| Sep 17, 2017 | $40M Venture Round | Bill & Melinda Gates Foundation | — | Announced |
| Jul 16, 2015 | $319.8M Venture Round | — | ELI Lilly And Company, Adrian Howd, RTW Investments, Neil Woodford | Announced |
Immunocore has raised $664.8M in total across 4 funding rounds.
Immunocore's investors include BlackRock, Oxford Finance, Rob Perez, Bill & Melinda Gates Foundation, CCB International, Eli Lilly and Company, JDRF T1D Fund, Rock Springs Capital, RTW Investments, Terra Magnum Capital Partners, WuXi AppTec, Adrian Howd.